Handelen Annexon, Inc. - ANNX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.06 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Annexon Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 3.11 |
| Open* | 3.15 |
| 1-Jaarlijkse Verandering* | -6.25% |
| Dagelijks bereik* | 2.98 - 3.2 |
| 52 wekelijks bereik | 2.07-7.65 |
| Weekgemiddelde volume (10 dagen) | 2.62M |
| Gemiddeld volume (3 maanden) | 16.80M |
| Marktkapitalisatie | 166.15M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 53.08M |
| Omzet | N/A |
| EPS | -2.47 |
| Dividend (opbrengst %) | N/A |
| Beta | -100.00K |
| Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 6, 2023 | 3.20 | 0.14 | 4.58% | 3.06 | 3.22 | 2.98 |
| Jun 5, 2023 | 3.11 | 0.15 | 5.07% | 2.96 | 3.23 | 2.87 |
| Jun 1, 2023 | 3.14 | 0.22 | 7.53% | 2.92 | 3.20 | 2.81 |
| May 31, 2023 | 2.97 | 0.14 | 4.95% | 2.83 | 3.03 | 2.60 |
| May 30, 2023 | 2.71 | 0.02 | 0.74% | 2.69 | 2.95 | 2.48 |
| May 26, 2023 | 2.78 | 0.71 | 34.30% | 2.07 | 2.81 | 2.05 |
| May 25, 2023 | 2.06 | -0.36 | -14.88% | 2.42 | 2.44 | 2.04 |
| May 24, 2023 | 5.15 | -0.33 | -6.02% | 5.48 | 5.63 | 5.05 |
| May 23, 2023 | 5.57 | -0.22 | -3.80% | 5.79 | 6.09 | 5.56 |
| May 22, 2023 | 5.94 | 0.27 | 4.76% | 5.67 | 6.04 | 5.66 |
| May 19, 2023 | 5.86 | 0.13 | 2.27% | 5.73 | 5.97 | 5.67 |
| May 18, 2023 | 5.76 | -0.47 | -7.54% | 6.23 | 6.61 | 5.72 |
| May 17, 2023 | 6.35 | 0.38 | 6.37% | 5.97 | 6.40 | 5.78 |
| May 16, 2023 | 6.00 | 0.06 | 1.01% | 5.94 | 6.15 | 5.77 |
| May 15, 2023 | 6.03 | 0.60 | 11.05% | 5.43 | 6.22 | 5.41 |
| May 12, 2023 | 5.44 | -0.02 | -0.37% | 5.46 | 5.59 | 5.41 |
| May 11, 2023 | 5.45 | -0.15 | -2.68% | 5.60 | 5.67 | 5.38 |
| May 10, 2023 | 5.59 | 0.20 | 3.71% | 5.39 | 5.79 | 5.35 |
| May 9, 2023 | 5.43 | 0.33 | 6.47% | 5.10 | 5.48 | 4.90 |
| May 8, 2023 | 5.21 | 0.17 | 3.37% | 5.04 | 5.26 | 5.03 |
Annexon, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Tijd (UTC) (UTC) 13:30 | Land US
| Evenement Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 9, 2023 | ||
| Tijd (UTC) (UTC) 16:00 | Land US
| Evenement Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Annexon Inc Earnings Release Q2 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q3 2023 Annexon Inc Earnings Release Q3 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 145.599 | 130.713 | 63.469 | 32.328 | 19.112 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 33.098 | 30.647 | 14.198 | 7.994 | 3.619 |
| Onderzoek & Ontwikkeling | 112.501 | 100.066 | 49.271 | 24.524 | 15.528 |
| Bedrijfsresultaat | -145.599 | -130.713 | -63.469 | -32.328 | -19.112 |
| Overige, Netto | 3.652 | 0.385 | 0.048 | -4.865 | 0.769 |
| Netto inkomen voor belastingen | -141.947 | -130.323 | -63.412 | -37.179 | -18.303 |
| Netto inkomen na belastingen | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Netto inkomen voor extra. Posten | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Totale buitengewone posten | |||||
| Netto inkomen | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Total Adjustments to Net Income | 0 | -6.924 | -1.095 | -0.176 | |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Verwaterd Netto Inkomen | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Verwaterd Gewogen Gemiddelde Aandelen | 54.6736 | 38.3163 | 16.9624 | 187.289 | 187.289 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.59626 | -3.40124 | -4.14658 | -0.20438 | -0.09867 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Verwaterde Genormaliseerde Winst per Aandeel | -2.59626 | -3.40124 | -4.14658 | -0.20504 | -0.09879 |
| Ongebruikelijke uitgaven (inkomsten) | -0.19 | -0.035 | |||
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.005 | 0.009 | 0.014 | 0.04 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 41.242 | 36.695 | 36.069 | 37.409 | 35.426 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 8.897 | 8.16 | 8.207 | 8.303 | 8.428 |
| Onderzoek & Ontwikkeling | 32.345 | 28.535 | 27.862 | 29.106 | 26.998 |
| Bedrijfsresultaat | -41.242 | -36.695 | -36.069 | -37.409 | -35.426 |
| Overige, Netto | 2.566 | 2.312 | 1.015 | 0.272 | 0.053 |
| Netto inkomen voor belastingen | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto inkomen na belastingen | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto inkomen voor extra. Posten | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto inkomen | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Total Adjustments to Net Income | |||||
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Verwaterd Netto Inkomen | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Verwaterd Gewogen Gemiddelde Aandelen | 73.8556 | 72.563 | 68.6529 | 38.5844 | 38.5634 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 248.098 | 247.693 | 354.011 | 45.406 | 45.706 |
| Geldmiddelen en kortetermijnbeleggingen | 242.657 | 242.715 | 351.206 | 43.931 | 44.175 |
| Geldmiddelen & Equivalenten | 140.02 | 74.843 | 268.565 | 43.931 | 44.175 |
| Prepaid Expenses | 5.238 | 4.515 | 2.802 | 1.396 | 1.306 |
| Total Assets | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Property/Plant/Equipment, Total - Net | 35.966 | 38.181 | 1.935 | 2.138 | 2.345 |
| Property/Plant/Equipment, Total - Gross | 38.849 | 38.97 | 3.906 | 3.442 | 3.156 |
| Accumulated Depreciation, Total | -2.883 | -0.789 | -1.971 | -1.304 | -0.811 |
| Other Long Term Assets, Total | 1.032 | 1.166 | 0 | 2.354 | 0.098 |
| Total Current Liabilities | 22.36 | 21.744 | 10.622 | 4.931 | 3.326 |
| Accounts Payable | 7.416 | 11.153 | 3.734 | 2.371 | 1.271 |
| Accrued Expenses | 14.764 | 10.452 | 6.497 | 2.194 | 1.713 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.18 | 0.139 | 0.391 | 0.366 | 0.342 |
| Total Liabilities | 53.902 | 55.131 | 11.668 | 6.368 | 5.129 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 31.542 | 33.387 | 1.046 | 1.437 | 1.803 |
| Total Equity | 231.194 | 231.909 | 344.278 | 43.53 | 43.02 |
| Redeemable Preferred Stock | 0 | 0 | 143.984 | 107.222 | |
| Common Stock | 0.048 | 0.039 | 0.038 | 0.004 | 0.004 |
| Additional Paid-In Capital | 669.78 | 528.365 | 510.309 | 2.202 | 1.257 |
| Retained Earnings (Accumulated Deficit) | -438.262 | -296.315 | -165.992 | -102.58 | -65.397 |
| Other Equity, Total | -0.372 | -0.18 | -0.077 | -0.08 | -0.066 |
| Total Liabilities & Shareholders’ Equity | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Total Common Shares Outstanding | 47.723 | 38.5608 | 38.1576 | 187.289 | 187.289 |
| Totale Vorderingen, Netto | 0 | 0.003 | 0.079 | 0.225 | |
| Korte Termijn Investeringen | 102.637 | 167.872 | 82.641 | ||
| Other Current Assets, Total | 0.203 | 0.463 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 232.536 | 248.098 | 274.777 | 181.372 | 211.254 |
| Geldmiddelen en kortetermijnbeleggingen | 228.165 | 242.657 | 269.519 | 177.594 | 206.659 |
| Geldmiddelen & Equivalenten | 144.12 | 140.02 | 210.658 | 104.614 | 112.828 |
| Korte Termijn Investeringen | 84.045 | 102.637 | 58.861 | 72.98 | 93.831 |
| Totale Vorderingen, Netto | |||||
| Prepaid Expenses | 4.206 | 5.238 | 5.201 | 3.741 | 4.461 |
| Total Assets | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Property/Plant/Equipment, Total - Net | 35.198 | 35.966 | 36.709 | 37.282 | 37.908 |
| Accumulated Depreciation, Total | -3.419 | -2.883 | -2.353 | -1.834 | -1.295 |
| Other Long Term Assets, Total | 1.044 | 1.032 | 1.236 | 2.05 | 1.407 |
| Total Current Liabilities | 22.941 | 22.36 | 20.22 | 20.254 | 17.053 |
| Accounts Payable | 10.346 | 7.416 | 6.921 | 10.301 | 9.378 |
| Accrued Expenses | 12.211 | 14.764 | 13.129 | 9.789 | 7.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.384 | 0.18 | 0.17 | 0.164 | 0.189 |
| Total Liabilities | 53.917 | 53.902 | 52.12 | 52.66 | 49.955 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 30.976 | 31.542 | 31.9 | 32.406 | 32.902 |
| Total Equity | 214.861 | 231.194 | 260.602 | 168.044 | 200.614 |
| Common Stock | 0.053 | 0.048 | 0.048 | 0.039 | 0.039 |
| Additional Paid-In Capital | 691.963 | 669.78 | 664.839 | 537.269 | 532.636 |
| Retained Earnings (Accumulated Deficit) | -476.938 | -438.262 | -403.879 | -368.825 | -331.688 |
| Other Equity, Total | -0.217 | -0.372 | -0.406 | -0.439 | -0.373 |
| Total Liabilities & Shareholders’ Equity | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Total Common Shares Outstanding | 53.0807 | 47.723 | 47.6265 | 38.6039 | 38.5636 |
| Property/Plant/Equipment, Total - Gross | 38.617 | 38.849 | 39.062 | 39.116 | 39.203 |
| Other Current Assets, Total | 0.165 | 0.203 | 0.057 | 0.037 | 0.134 |
| Redeemable Preferred Stock |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Geldmiddelen uit Operationele Activiteiten | -116.309 | -106.11 | -53.087 | -28.358 | -17.19 |
| Geldmiddelen uit Operationele Activiteiten | 2.106 | 2.141 | 0.667 | 0.493 | 0.488 |
| Niet-Geldelijke Posten | 19.794 | 18.788 | 4.941 | 7.707 | 0.148 |
| Cash Taxes Paid | 0 | 0.002 | 0.001 | ||
| Veranderingen in het Operationeel Kapitaal | 3.738 | 3.284 | 4.717 | 0.625 | 0.478 |
| Geldmiddelen uit Investeringsactiviteiten | 58.443 | -88.236 | -83.164 | -0.267 | -0.017 |
| Kapitaaluitgaven | -6.526 | -1.654 | -0.464 | -0.267 | -0.017 |
| Geldmiddelen uit Financieringsactiviteiten | 122.908 | 1.795 | 360.876 | 28.395 | 58.456 |
| Uitgifte (Aflossing) van aandelen, netto | 130.896 | 1.795 | 363.85 | 30 | 58.456 |
| Wisselkoerseffecten | 0.001 | -0.005 | 0.009 | -0.014 | -0.04 |
| Nettowijziging in Geldmiddelen | 65.043 | -192.556 | 224.634 | -0.244 | 41.209 |
| Financiering van Cash Flow Posten | -7.988 | 0 | -2.974 | -1.605 | 0 |
| Overige Cash Flow investeringsposten, Totaal | 64.969 | -86.582 | -82.7 | ||
| Uitgifte (Aflossing) van Schulden, Netto | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -38.676 | -141.947 | -107.564 | -72.51 | -35.373 |
| Cash From Operating Activities | -32.993 | -116.309 | -89.17 | -58.452 | -30.288 |
| Cash From Operating Activities | 0.536 | 2.106 | 1.576 | 1.058 | 0.518 |
| Non-Cash Items | 3.969 | 19.794 | 14.89 | 9.842 | 4.862 |
| Changes in Working Capital | 1.178 | 3.738 | 1.928 | 3.158 | -0.295 |
| Cash From Investing Activities | 19.517 | 58.443 | 102.058 | 87.96 | 68.251 |
| Capital Expenditures | -0.137 | -6.526 | -6.244 | -6.075 | -5.214 |
| Other Investing Cash Flow Items, Total | 19.654 | 64.969 | 108.302 | 94.035 | 73.465 |
| Cash From Financing Activities | 17.581 | 122.908 | 122.8 | 0.132 | 0.019 |
| Financing Cash Flow Items | -7.988 | -7.853 | |||
| Issuance (Retirement) of Stock, Net | 17.581 | 130.896 | 130.653 | 0.132 | 0.019 |
| Foreign Exchange Effects | -0.005 | 0.001 | -0.007 | -0.003 | 0.003 |
| Net Change in Cash | 4.1 | 65.043 | 135.681 | 29.637 | 37.985 |
| Issuance (Retirement) of Debt, Net |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Satter Management Co., L.P. | Private Equity | 13.2922 | 7056024 | 0 | 2023-03-31 | MED |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 10.7413 | 5701926 | 815310 | 2023-05-25 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 6.6875 | 3549975 | 0 | 2023-03-31 | MED |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.5993 | 3503190 | 0 | 2023-03-31 | LOW |
| VR Adviser, LLC | Venture Capital | 6.066 | 3220050 | 0 | 2023-03-31 | MED |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 5.7603 | 3057800 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 4.5459 | 2413117 | -87190 | 2023-03-31 | HIGH |
| Eventide Asset Management, LLC | Investment Advisor | 3.5175 | 1867250 | -1759258 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9575 | 1569971 | 21100 | 2023-03-31 | LOW |
| GMT Capital Corp. | Hedge Fund | 2.6537 | 1408697 | 1408697 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 2.5702 | 1364343 | 837812 | 2023-03-31 | HIGH |
| Cormorant Asset Management, LP | Hedge Fund | 2.3548 | 1250000 | 1250000 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.3222 | 1232713 | 0 | 2023-03-31 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 2.2417 | 1190000 | 1190000 | 2023-03-31 | MED |
| Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 2.0552 | 1090986 | -200586 | 2023-03-31 | HIGH |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.9183 | 1018303 | 1018303 | 2023-03-31 | LOW |
| Polar Capital LLP | Investment Advisor/Hedge Fund | 1.8838 | 1000000 | 1000000 | 2023-03-31 | LOW |
| Soleus Capital Management, L.P. | Hedge Fund | 1.7244 | 915400 | 915400 | 2023-03-31 | HIGH |
| Novartis AG | Corporation | 1.7157 | 910747 | -1196497 | 2021-12-31 | LOW |
| Clarus Ventures, LLC | Venture Capital | 1.7147 | 910211 | 0 | 2023-03-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Annexon, Inc. Company profile
Over Annexon, Inc.
Annexon, Inc. is een biofarmaceutisch bedrijf in klinische ontwikkeling dat een pijplijn van therapieën ontwikkelt voor patiënten met klassieke complement-gemedieerde aandoeningen van het lichaam, de hersenen en het oog. De productkandidaat van het bedrijf, ANX005, is een monoklonaal full-length antilichaam voor intraveneuze toediening bij auto-immuunziekten en neurodegeneratieve aandoeningen. Haar productkandidaat, ANX007, is een antigen-bindend fragment (Fab), geformuleerd voor intravitreale toediening voor de behandeling van neurodegeneratieve oftalmologische aandoeningen. Het ontwikkelt ook ANX009, een subcutane formulering van een Fab voor de behandeling van systemische auto-immuunziekten. Het bedrijf heeft fase 1b veiligheids- en dosisafhankelijke klinische studies afgerond voor ANX005 en ANX007 bij patiënten met respectievelijk Guillain-Barre Syndroom (GBS) en glaucoom. Het bedrijf voert ook klinische studies uit voor meerdere ernstige auto-immuunziekten, neurodegeneratieve ziekten en oogaandoeningen.
| Industry: | Biopharmaceuticals |
1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen